Pioglitazone on Cardiac Function and Large Arteries (PICCOLA Study)

Diabetes Clinical Trial

— PICCOLA  

Official title:

Pioglitazone on Cardiac Function and Large Arteries (PICCOLA)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00485056
• Other study ID #: EU-IIT-006
• Status: Completed
• Phase: Phase 4
• First received: June 11, 2007
• Last updated: August 8, 2016
• Start date: April 2008
• Est. completion date: April 2010

Study information

• Verified date: August 2009
• Source: Imperial College London
• Contact: n/a
• Is FDA regulated: No
• Health authority: United Kingdom: Medicines and Healthcare Products Regulatory AgencyUnited Kingdom: National Health ServiceUnited Kingdom: Research Ethics Committee
• Study type: Interventional

Clinical Trial Summary

This study aims to use a novel, sensitive, non-invasive scanning technique to investigate the effects of insulin-sensitizing agent pioglitazone, on heart and artery function.

Description:

The prevalence of diabetes mellitus and impaired glucose tolerance are nearing epidemic proportions in developed societies. For example in the USA >16 million individuals have diabetes and this number is predicted to double over the next two decades. Diabetes is a major risk factor for death and disability, primarily from cardiovascular disease (CVD).

The mechanisms of how diabetes increases the risk of developing CVD are not fully understood. It is evident from previous studies that diabetes has an adverse effect on both artery and heart function. What is emerging from recent studies is that it is likely that these proven dysfunctions in the arteries and heart interact to increase the risk of CVD.

Insulin-sensitizing agents, such as Pioglitazone, may have a beneficial effect on heart and artery function. This study aims to further our understanding of the effect of these agents on heart and artery using a novel, sensitive, non-invasive scanning technique to investigate the effects of this group of drugs on heart and artery function.

This is a prospective double-blind randomised crossover study comparing the insulin-sensitizing drug, Pioglitazone with a placebo in 24 volunteers. Following a >1 week run-in period subjects will be randomised double-blind to 1 of 2 treatment sequences. Subjects will either receive the active drug (Pioglitazone 45mg/day) for a 12 week period, followed by a 2 week washout and then the placebo drug for 12 weeks OR they will receive the placebo drug for 12 weeks, followed by the 2 week washout and 12 weeks of the active drug (Pioglitazone 45mg/day).

This design was chosen to test the null hypothesis that the active drug will have no effect on diastolic heart function. The use of a placebo is essential to ensure that any benefits found can be attributed to the active drug. The design also allows us to minimise the number of subjects needed and is the gold standard approach to avoid observer bias.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: April 2010
• Est. primary completion date: April 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Male or female of any age with Type 2 Diabetes

Exclusion Criteria:

• Subjects will be excluded if they have any of the following:

• Known coronary heart disease,

• Patients receiving Insulin,

• Uncontrolled hypertension (i.e. >160mmHg systolic or >95mmHg diastolic),

• Systolic dysfunction (ejection fraction <50%),

• Heart Valve Disease,

• Proliferative or pre-proliferative retinopathy,

• Severe hepatic or renal impairment.

• Possible pregnancy

• Malignancy

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science

Related Conditions & MeSH terms

• Diabetes

Intervention

Drug:
• Pioglitazone
45mgs daily

Locations

Country	Name	City	State
United Kingdom	International Centre for Circulatory Health	London

Sponsors (1)

Lead Sponsor	Collaborator
Imperial College London

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The primary endpoint will be the TDI E' ratio which is the relatively preload independent measure of ventricular diastolic function.		26 weeks	No
Secondary	E/E' measured by TDI (a non-invasive measure of preload).		26 weeks	No